# Apollo Hospitals: how the business works

> For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Apollo Hospitals Enterprise Limited · NSE: APOLLOHOSP · BSE: 508869 · Sector: Healthcare

Updated for Q2 FY27 · checked 12 Nov 2026

This is the plain-text version of https://cityfort.in/stocks/apollo-hospitals. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, Apollo Hospitals: how the business works", with the page URL.

## In short

Patients, insurers and pharmacy stores pay Apollo for treatment and medicines; just over half of every ₹100 goes on medicines and supplies, and ₹7.6 is left as profit.

- Hospitals were 50.1% of FY26 segment revenue but earned 84.0% of segment profit (₹2,430 crore of ₹2,893 crore; Cityfort calculation from the FY26 results).
- Pharmacy distribution and Apollo 24/7 were 42.5% of segment revenue. A scheme awaiting tribunal sanction moves them into a separate listed company, Apollo Healthtech.

## Key facts

**What does Apollo Hospitals do?**

Apollo Hospitals Enterprise Ltd (Apollo Hospitals) runs private hospitals in India: 48 of its own, with 8,522 operating beds, on 30 Sep 2026. Through its subsidiary Apollo HealthCo it also supplies 7,662 Apollo pharmacy stores and runs the Apollo 24/7 health app. [S18]

**How does Apollo Hospitals make money?**

Apollo Hospitals charges for treatment in its hospitals and earns a margin on the medicines it supplies. In FY26 hospitals were 50.1% of Apollo Hospitals' segment revenue but earned ₹2,430 crore of its ₹2,893 crore segment profit before interest and tax. [S7]

**Who pays Apollo Hospitals?**

Insurance companies and patients paying for themselves gave 82% of Apollo Hospitals' inpatient revenue in Q2 FY27, the company said on its 5 Nov 2026 earnings call. Pharmacy stores and online medicine buyers paid for 42.5% of Apollo Hospitals' FY26 segment revenue. [S22, S7]

**How big is Apollo Hospitals?**

Apollo Hospitals' FY26 revenue was ₹24,774 crore, re-presented without the Cradle and Fertility units it sold in Oct 2026, and its FY26 profit for shareholders was ₹1,942 crore. Apollo Hospitals' Q2 FY27 revenue was ₹7,615 crore. [S4, S7, S5]

**Who owns Apollo Hospitals?**

On 30 Sep 2026 Apollo Hospitals' promoter group held 28.02% of the shares, foreign investors 43.18%, Indian institutions 22.07%, individuals and others 6.49% and state governments 0.23%. 2.91% of the promoter group's Apollo Hospitals shares were pledged as loan collateral. [S26]

**What is the Apollo Healthtech scheme?**

Apollo Hospitals' board approved a scheme on 30 Jun 2025 to move the pharmacy distribution and Apollo 24/7 business into Apollo Healthtech Ltd, which would list on the stock exchanges. Apollo Hospitals shareholders would get 195.2 Apollo Healthtech shares for every 100 Apollo Hospitals shares. The scheme had not taken effect on 30 Sep 2026. [S40, S4]

**What dividend does Apollo Hospitals pay?**

Apollo Hospitals declared ₹20 a share for FY26 (₹10 interim and ₹10 final), up from ₹19 a share for FY25 and ₹16 for FY24. [S1, S53]

**How much does Apollo Hospitals borrow?**

On 30 Sep 2026 Apollo Hospitals reported borrowings of ₹5,595 crore and cash and short-term investments of ₹2,381 crore. On 31 Mar 2026, ₹2,457 crore of Apollo Hospitals' reported borrowings were preference shares that must convert into shares of its subsidiary Apollo HealthCo. [S5, S1]

## What does Apollo Hospitals sell?

Apollo runs private hospitals where patients get surgery, cancer care, transplants and other complex treatment. Its subsidiary Apollo HealthCo supplies medicines to Apollo pharmacy stores and runs the Apollo 24/7 app. A third arm runs clinics and diagnostic centres.

- **Hospitals:** 48 hospitals of its own with 8,522 operating beds on 30 Sep 2026, plus 6 it manages for other owners. Heart, cancer, brain, gut, bone and transplant care made up 61% of inpatient revenue in Q2 FY27. [S18, S22]
- **Pharmacy distribution (Apollo HealthCo):** Supplies medicines to 7,662 Apollo pharmacy stores (30 Sep 2026). Apollo's own private-label and generic products were about 15.3% of omni-channel pharmacy sales in Q2 FY27. [S18]
- **Apollo 24/7 app:** An app for ordering medicines, seeing a doctor online and booking tests: over 51 million registered users, about 57,400 medicine orders and 16,400 consultations a day in Q2 FY27. [S18]
- **Clinics and diagnostics (AHLL):** Apollo Health and Lifestyle runs 292 primary-care clinics, 2,922 diagnostic collection points, 23 Spectra units, 196 dialysis centres and 300 dental clinics (30 Sep 2026). [S18]

## Who pays Apollo Hospitals?

- **Hospital patients, their insurers and government schemes (50.1% of revenue):** Pay for treatment in Apollo's hospitals. Management said insurance and self-paying patients gave 82% of inpatient revenue in Q2 FY27; the company's other payer groups are public-sector and government payers, and international patients. [S7, S22, S18]
- **Pharmacy stores and online medicine buyers (42.5% of revenue):** Apollo HealthCo's revenue from supplying Apollo pharmacy stores and from online sales through Apollo 24/7. Offline pharmacy distribution was ₹2,885 crore of its ₹3,286 crore revenue in Q2 FY27. [S7, S18]
- **Clinic, diagnostics and day-surgery patients (7.3% of revenue):** AHLL's revenue. In Q2 FY27, diagnostics brought in ₹227 crore, primary care ₹139 crore and specialty care ₹84 crore. [S7, S18]
- **Customer concentration:** Shares are each segment's FY26 revenue before sales between segments, divided by their total of ₹25,429 crore (Cityfort calculation from the FY26 results). The filings collected give no revenue by single customer. CRISIL says Apollo HealthCo is the exclusive supplier of the Apollo pharmacy stores run by Apollo Pharmacies Ltd. [S7, S38]

## Where the money went (FY26)

1. In FY26 Apollo's hospitals, pharmacy supply and clinics brought in ₹25,229 crore as first reported, plus ₹192 crore of other income.
2. Medicines, consumables and goods bought for resale took ₹13,076 crore, the biggest cost.
3. Employees took ₹3,000 crore and other running costs ₹5,383 crore.
4. Depreciation and interest took ₹1,326 crore, and income tax ₹658 crore.
5. After ₹35 crore of smaller items, ₹1,942 crore was left as profit for Apollo's shareholders.

Sources: S7, S4.

## Key numbers by year (₹ crore)

Financials: consolidated, ₹ crore. Financial year runs April to March (March year end). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (₹ per share) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY22 | 14,663 | 2,479 | 16.9% | 1,056 | 7.2% | 73.42 | 1,616 | 657 | 959 | S17 |
| FY23 | 16,613 | 2,050 | 12.3% | 819 | 4.9% | 56.97 | 1,377 | 1,129 | 249 | S16 |
| FY24 | 19,059 | 2,393 | 12.6% | 899 | 4.7% | 62.5 | 1,920 | 1,137 | 784 | S15 |
| FY25 | 21,794 | 3,022 | 13.9% | 1,446 | 6.6% | 100.56 | 2,136 | 1,713 | 424 | S11 |
| FY26 (restated) | 24,774 | — | — | 1,942 | 7.7% | 135.04 | 2,856 | 1,962 | 894 | S4, S7, S1 |

- EBITDA = profit before interest, tax and wear-and-tear of assets.
- Net profit is the share belonging to the company's owners.

## Balance sheet (as of 30 Sep 2026, ₹ crore)

On 30 Sep 2026 Apollo's reported borrowings were ₹3,214 crore more than its cash and short-term investments; part of those borrowings are preference shares that convert into shares, not repayments. [S5, S1, S18]

| Item | Value |
| --- | --- |
| Total debt | 5,595 |
| Cash and investments | 2,381 |
| Net debt (debt minus cash) | 3,214 |
| Net worth (shareholders' money) | 10,604 |
| Debt to equity (times) | 0.53 |

- Reported borrowings include compulsorily convertible preference shares (CCPS) that Apollo HealthCo issued to Rasmeli, an associate of the private equity fund Advent International, for ₹2,475 crore. They must convert into Apollo HealthCo shares within 19 years and 9 months, or earlier on set events.
- On 31 Mar 2026 the CCPS were ₹2,457 crore of reported borrowings of ₹5,659 crore. Without them, borrowings were ₹3,201 crore (Cityfort calculation: ₹5,659 crore − ₹2,457 crore, FY26 annual report).
- Management estimated on 31 Mar 2026 that the CCPS would convert within a year, so they were moved to short-term borrowings.
- The 30 Sep 2026 results do not give the CCPS amount. The company's own gross debt for that date, which leaves them out, was ₹3,132 crore, and its net debt ₹629 crore (Q2 FY27 deck).
- Lease liabilities (rent owed under leases), ₹2,834 crore on 31 Mar 2026, are not part of borrowings.
- Debt-to-equity here = reported borrowings ÷ equity of Apollo's shareholders (₹10,604 crore), a Cityfort calculation. The annual report gives 0.26 for FY26 on the company's own gross-debt basis.
- Cash and short-term investments = cash, other bank balances and current investments.

## Who owns Apollo Hospitals? (shareholding, Q2 FY27)

| Holder | % of shares |
| --- | --- |
| Promoters | 28.02% |
| Promoter shares pledged (% of promoter shares) | 2.91% |
| Foreign institutions (FII) | 43.18% |
| Indian institutions (DII) | 22.07% |
| Public | 6.49% |
| State governments | 0.23% |

Sources: S26, S27, S28, S29, S30, S31, S32, S33, S34, S35, S36, S37.

## What could go wrong

### Demerger of pharmacy and Apollo 24/7

A scheme would move pharmacy distribution and Apollo 24/7, 42.5% of FY26 segment revenue, into Apollo Healthtech. CRISIL says Apollo would keep an economic interest of about 17.5%. Shareholders approved it on 24 Jun 2026; tribunal sanction was pending at the Q2 FY27 results. No restated history without the business has been published. [S40, S7, S38, S49, S4, S22]

What to watch: NCLT Chennai's sanction and the first results after the demerger; management said on 5 Nov 2026 it expects completion in Q4 FY27.

### Price controls on treatment and devices

CRISIL notes that government price caps on cardiac stents and knee implants hurt Apollo's revenue and profit in FY17 and FY18. States also capped Covid treatment charges in 2020. [S38]

What to watch: Government notices capping prices of procedures, devices or medicines.

### New hospitals take time to fill

Apollo is opening 1,395 census beds across FY26 and FY27; 520 were open by Sep 2026. The company puts its full expansion plan at about ₹11,150 crore, with about ₹7,100 crore still to spend. New hospitals lost ₹35 crore of EBITDA in Q2 FY27. [S18, S22, S24]

What to watch: New-hospital losses each quarter against the ₹150 crore FY27 figure management gave, and Gurugram's opening.

### Promoter shares pledged

On 30 Sep 2026, 2.91% of the promoter group's shares were pledged as loan collateral, up from 2.49% in Jun 2026 and down from 16.09% in Dec 2023. In Aug 2025 the promoter group sold 1.3% of Apollo to reduce promoter-group debt. [S26, S27, S37, S41]

What to watch: The pledge level in each quarterly shareholding filing.

### Karnataka land order

Karnataka's Revenue Department cancelled a land grant to subsidiary Imperial Hospitals & Research Centre on 13 Feb 2026, alleging the land was alienated through a share purchase by its holding company. The High Court granted an interim stay against the order on 10 Apr 2026. Apollo says external legal opinions give it adequate grounds to show compliance. No amount is stated. [S4]

What to watch: The High Court of Karnataka's decision.

### Apollo 24/7 still near break-even

CRISIL says Apollo spent about ₹640 crore a year on Apollo 24/7 in FY23 and FY24, which pushed the pharmacy business into operating losses. The digital business made a ₹1.3 crore cash profit before ESOP costs in Q2 FY27, but an ₹8.3 crore cash loss in H1 FY27. [S38, S18, S24]

What to watch: Q3 FY27 digital results including ESOP costs, the milestone management gave in May 2026.

### Leadership and auditor changes

Dr Madhu Sasidhar, President and CEO of the hospitals division, leaves on 14 Nov 2026. Dinesh Madhavan, President of Group Oncology and International, resigned in May 2026. Deloitte's final term as auditor ends at the 2027 annual meeting. [S4, S48, S1]

What to watch: Who leads the hospitals division and who becomes the next auditor.

## What to watch

Next: Q3 FY27 results, Date not announced yet.

- **Tribunal sanction of the demerger:** NCLT Chennai has to sanction the Apollo Healthtech scheme. Management said on 5 Nov 2026 it expects completion in Q4 FY27.
- **Gurugram and new-hospital losses:** Group CFO A. Krishnan said on 5 Nov 2026 that Gurugram would launch in the coming quarter. New hospitals lost ₹35 crore of EBITDA in Q2 FY27.
- **Apollo 24/7 after ESOP costs:** In May 2026 Apollo HealthCo's CFO said digital should break even including ESOP costs by Q3 FY27. Q2 FY27 showed a ₹1.3 crore cash profit before them.
- **Hospital leadership:** Dr Madhu Sasidhar leaves on 14 Nov 2026; his functions move to an office under the MD.

## Sources

- S1: Annual Report FY26 (updated version, re-filed 28 Aug 2026). Apollo Hospitals Enterprise Ltd (filed with NSE). https://nsearchives.nseindia.com/annual_reports/AR_30779_APOLLOHOSP_2025_2026_U_16736806_28082026154612.pdf (published 28 Aug 2026)
- S4: Q2 FY27 results: outcome of board meeting, unaudited results, notes, change in senior management (4 Nov 2026). Apollo Hospitals Enterprise Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/APOLLOHOSP_04112026174756_SE_Communication_04112026_s.pdf (published 4 Nov 2026)
- S5: Q2 FY27 consolidated results, XBRL (integrated filing). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752991_04112026070517_WEB.xml (published 4 Nov 2026)
- S6: Q1 FY27 consolidated results, XBRL (integrated filing). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1713097_12082026082030_WEB.xml (published 12 Aug 2026)
- S7: Q4 FY26 and FY26 audited consolidated results, XBRL (integrated filing). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1670330_20052026101739_WEB.xml (published 20 May 2026)
- S8: Q3 FY26 consolidated results, XBRL (integrated filing). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1622729_10022026064120_WEB.xml (published 10 Feb 2026)
- S9: Q2 FY26 consolidated results, XBRL (integrated filing). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1567122_06112025061828_WEB.xml (published 6 Nov 2025)
- S10: Q1 FY26 consolidated results, XBRL (integrated filing). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1510465_12082025082558_WEB.xml (published 12 Aug 2025)
- S11: Q4 FY25 and FY25 audited consolidated results, XBRL (integrated filing). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1460889_30052025104552_WEB.xml (published 30 May 2025)
- S12: Q3 FY25 consolidated results, XBRL. NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_119560_1377813_11022025023124.xml (published 10 Feb 2025)
- S13: Q2 FY25 consolidated results, XBRL. NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_114392_1300211_07112024053847.xml (published 6 Nov 2024)
- S14: Q1 FY25 consolidated results, XBRL. NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_112156_1225645_14082024042130.xml (published 14 Aug 2024)
- S15: Q4 FY24 and FY24 audited consolidated results, XBRL. NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_108616_1150927_31052024060453.xml (published 31 May 2024)
- S16: Q4 FY23 and FY23 audited consolidated results, XBRL. NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_93944_860486_31052023045133.xml (published 31 May 2023)
- S17: Q4 FY22 and FY22 audited consolidated results, XBRL. NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_85621_662120_26052022070436_WEB.xml (published 26 May 2022)
- S18: Earnings update Q2 FY27 (investor presentation). Apollo Hospitals Enterprise Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/APOLLOHOSP_04112026184717_SE_Investors_Presentation.pdf (published 4 Nov 2026)
- S19: Earnings update Q1 FY27 (investor presentation). Apollo Hospitals Enterprise Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/APOLLOHOSP_12082026213756_investor_presentation.pdf (published 12 Aug 2026)
- S22: Transcript of Q2 FY27 earnings call (5 Nov 2026). Apollo Hospitals Enterprise Ltd (company site; link filed with NSE 11 Nov 2026). https://www.apollohospitals.com/sites/default/files/2026-11/transcript-of-apollo-hospitals---q2-fy27-earnings-call.pdf (published 11 Nov 2026)
- S24: Transcript of Q4 FY26 earnings call (21 May 2026). Apollo Hospitals Enterprise Ltd (company site; link filed with NSE 25 May 2026). https://www.apollohospitals.com/sites/default/files/2026-05/transcript-of-apollo-hospitals---q4-fy26-earnings-call.pdf (published 25 May 2026)
- S25: Transcript of Q3 FY26 earnings call (11 Feb 2026). Apollo Hospitals Enterprise Ltd (company CDN; link filed with NSE 14 Feb 2026). https://drupal-cdn-hfaeddcdbng5hfbg.a01.azurefd.net/sites/default/files/2026-02/transcript-of-ahel-q3fy26-concall_11feb2026.pdf (published 14 Feb 2026)
- S26: Shareholding pattern, quarter ended Sep 2026 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1733654_07102026112959_WEB.xml (published 7 Oct 2026)
- S27: Shareholding pattern, quarter ended Jun 2026 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1687831_03072026043226_WEB.xml (published 3 Jul 2026)
- S28: Shareholding pattern, quarter ended Mar 2026 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1648111_09042026045634_WEB.xml (published 9 Apr 2026)
- S29: Shareholding pattern, quarter ended Dec 2025 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1595494_06012026034140_WEB.xml (published 6 Jan 2026)
- S30: Shareholding pattern, quarter ended Sep 2025 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1574387_13112025091028_WEB.xml (published 8 Oct 2025)
- S31: Shareholding pattern, quarter ended Jun 2025 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1478621_08072025032200_WEB.xml (published 8 Jul 2025)
- S32: Shareholding pattern, quarter ended Mar 2025 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_196718_1411557_10042025022517_WEB.xml (published 10 Apr 2025)
- S33: Shareholding pattern, quarter ended Dec 2024 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_194792_1346804_16012025104509_WEB.xml (published 16 Jan 2025)
- S34: Shareholding pattern, quarter ended Sep 2024 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_191373_1263042_09102024025509_WEB.xml (published 9 Oct 2024)
- S35: Shareholding pattern, quarter ended Jun 2024 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_188834_1176041_09072024024959_WEB.xml (published 9 Jul 2024)
- S36: Shareholding pattern, quarter ended Mar 2024 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_185949_1082833_08042024112500_WEB.xml (published 8 Apr 2024)
- S37: Shareholding pattern, quarter ended Dec 2023 (XBRL). NSE (company XBRL filing). https://nsearchives.nseindia.com/corporate/xbrl/SHP_183243_1008394_05012024023758_WEB.xml (published 5 Jan 2024)
- S38: Crisil Ratings rating rationale: AHEL bank facilities and NCDs, CRISIL AA+/Positive and CRISIL A1+ (filed with NSE 27 Jan 2026). Crisil Ratings Ltd (letter filed by the company with NSE). https://nsearchives.nseindia.com/corporate/APOLLOHOSP_27012026181751_SE_CRISILRATINGS.pdf (published 27 Jan 2026)
- S39: ICRA rating letter: [ICRA]AAA (Stable) and [ICRA]A1+ assigned on Rs 3,000 crore of facilities (letter dated 18 May 2026). ICRA Ltd (letter filed by the company with NSE). https://nsearchives.nseindia.com/corporate/APOLLOHOSP_19052026113432_SE_LET-ICRA.pdf (published 19 May 2026)
- S40: Board approves composite scheme: demerger of omni-channel pharmacy and digital health into Apollo Healthtech Ltd, amalgamation of Apollo HealthCo and Keimed, listing (30 Jun 2025). Apollo Hospitals Enterprise Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/APOLLOHOSP_30062025194532_SE_communication_30062025.pdf (published 30 Jun 2025)
- S41: Promoter group sells 1,897,239 shares (1.3%) by block deal; pledge update (22 Aug 2025). Apollo Hospitals Enterprise Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/APOLLOHOSP_22082025093759_SE_commun_22082025.pdf (published 22 Aug 2025)
- S42: Board outcome: purchase of 30.58% of AHLL from IFC for Rs 12,540.68 million; Gurugram oncology and proton centre (12 Sep 2025). Apollo Hospitals Enterprise Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/APOLLOHOSP_12092025191243_SE_communication_12092025.pdf (published 12 Sep 2025)
- S44: Completion of AHLL stake purchase from IFC and IFC EAF; holding 99.42% (23 Mar 2026). Apollo Hospitals Enterprise Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/APOLLOHOSP_23032026123242_SE_Letter-IFC_EAF_0001.pdf (published 23 Mar 2026)
- S45: AHLL becomes a 100% subsidiary after purchase from individual shareholders (10 Apr 2026). Apollo Hospitals Enterprise Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/APOLLOHOSP_10042026183147_SE_let_AHLL.pdf (published 10 Apr 2026)
- S47: Press release: Apollo Cradle and Fertility combine with Cloudnine, valued at Rs 1,550 crore (cash plus 9.9% stake) (20 May 2026). Apollo Hospitals Enterprise Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/APOLLOHOSP_20052026194741_se_press_release.pdf (published 20 May 2026)
- S48: Resignation of Dinesh Madhavan, President - Group Oncology and International (30 May 2026). Apollo Hospitals Enterprise Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/APOLLOHOSP_30052026151030_SE_LET_SMP.pdf (published 30 May 2026)
- S49: Proceedings of the NCLT-convened meeting of equity shareholders on the composite scheme (24 Jun 2026). Apollo Hospitals Enterprise Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/APOLLOHOSP_24062026205745_se_nclt_proceedings_1.pdf (published 24 Jun 2026)
- S50: NSE historical price data, APOLLOHOSP (EQ series), 2-11 Nov 2026. National Stock Exchange of India. https://www.nseindia.com/api/historicalOR/generateSecurityWiseHistoricalData?from=01-11-2026&to=11-11-2026&symbol=APOLLOHOSP&type=priceVolumeDeliverable&series=EQ (published 11 Nov 2026)
- S51: Business Responsibility and Sustainability Report FY26 (section of Annual Report FY26). Apollo Hospitals Enterprise Ltd (filed with NSE). https://nsearchives.nseindia.com/annual_reports/AR_30779_APOLLOHOSP_2025_2026_U_16736806_28082026154612.pdf (published 28 Aug 2026)
- S53: NSE corporate announcements list for APOLLOHOSP (dividend and record-date entries, Feb 2023 - Nov 2026). National Stock Exchange of India. https://www.nseindia.com/api/corporate-announcements?index=equities&symbol=APOLLOHOSP (published 11 Nov 2026)
